The studies described in this proposal are designed to further our understanding of the structure and function of antibody molecules, the relationship of immune complexes to human disease and the characterization of the major protein constituents of amyloid. The experiments dealing with antibody molecules and immunoglobulin variants produced by normal individuals as well as those with multiple myeloma and related plasma cell neoplasms are expected to shed insight into the genetic control of immunoglobulin structure and synthesis, to define the antibody combining sites and the expression of novel immunoglubulin genes. We wish to determine the factors involved in the production of rheumatoid factor cryoglobulins which result in an immune complex type of nephritis and vasculitis. Finally, we are attempting to classify from a clinical, immunohistologic and biochemical point of view a heterogeneous group of diseases characterized by the deposition of amyloid fibrils. Our approach is based on the theory that all types of amyloidosis occur in individuals who are genetically or otherwise defective in processing a soluble precursor which is a normal serum component.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR002594-30
Application #
3154648
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1978-09-01
Project End
1989-03-31
Budget Start
1987-09-01
Budget End
1989-03-31
Support Year
30
Fiscal Year
1987
Total Cost
Indirect Cost
Name
New York University
Department
Type
Schools of Medicine
DUNS #
004514360
City
New York
State
NY
Country
United States
Zip Code
10012
Sigurdsson, Einar M (2006) Immunotherapy for conformational diseases. Curr Pharm Des 12:2569-85
Goni, Fernando; Sigurdsson, Einar M (2005) New directions towards safer and effective vaccines for Alzheimer's disease. Curr Opin Mol Ther 7:17-23
Goni, F; Knudsen, E; Schreiber, F et al. (2005) Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133:413-21
Sigurdsson, Einar M; Knudsen, Elin; Asuni, Ayodeji et al. (2004) An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 24:6277-82
Berasain, Patricia; Carmona, Carlos; Frangione, Blas et al. (2003) Specific cleavage sites on human IgG subclasses by cruzipain, the major cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 130:23-9
Sigurdsson, Einar M; Brown, David R; Alim, Muhammad A et al. (2003) Copper chelation delays the onset of prion disease. J Biol Chem 278:46199-202
Sigurdsson, Einar M; Brown, David R; Daniels, Maki et al. (2002) Immunization delays the onset of prion disease in mice. Am J Pathol 161:13-7
Sigurdsson, E M; Scholtzova, H; Mehta, P D et al. (2001) Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 159:439-47
Aucouturier, P; Geissmann, F; Damotte, D et al. (2001) Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie. J Clin Invest 108:703-8
Vidal, R; Calero, M; Revesz, T et al. (2001) Sequence, genomic structure and tissue expression of Human BRI3, a member of the BRI gene family. Gene 266:95-102

Showing the most recent 10 out of 65 publications